# Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population

> **NCT02000531** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 45 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT02000531
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000531, "Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02000531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*